Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

U.S. appeals court rejects novel opioid settlement framework

Published 09/24/2020, 11:28 AM
Updated 09/24/2020, 12:40 PM
© Reuters.
CAH
-
MCK
-
COR
-

By Nate Raymond

(Reuters) - A federal appeals court on Thursday overturned a judge's approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.

The 6th U.S. Circuit Court of Appeals by a 2-1 vote declined to approve an unprecedented "negotiation class" of 33,000 cities, towns and counties who could have a vote on whether to accept any settlements proposed with drug manufacturers and distributors.

U.S. District Judge Dan Polster in Cleveland, who oversees 2,900 opioid lawsuits, approved the framework last year to promote a global settlement.

It would allow cities and counties that have not sued to participate in settlement talks. Any settlement would need to win support of at least 75% of class members to be approved.

While companies do not have to use the negotiation class to settle cases, many including the drug distributors McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH) and AmerisourceBergen (NYSE:ABC) Corp objected.

Many state attorneys general, who have cases against the companies not before Polster, also objected, arguing the ruling could complicate their own settlement talks and interfere with states' rights over their political subdivisions.

U.S. Circuit Judge Eric Clay said the federal rule that allows for class actions to jointly litigate cases does not authorize what Polster approved.

"However well-intentioned the district court’s actions might be, the fact of the matter is that the court, when it certified the negotiation class, exercised power it did not have," he wrote.

The plaintiffs' lawyers and companies did not immediately comment.

Some companies have proposed deals that do not use the framework including the three distributors and drugmakers Johnson & Johnson and Teva Pharmaceutical Industries (NYSE:TEVA) Ltd, who in October 2019 proposed deals worth a collective $48 billion.

Negotiations are ongoing and dollar amounts have been shifting.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.